| BIOGEN INC | 210.39 / +0.86% |
| Date/Time | 08/23 / 09:05 |
| Chg. / Chg.(%) | 1.79 / +0.86% |
| Bid | 209.31 / 48 |
| Ask | 211.19 / 48 |
| Open | 210.39 |
| Previous Close | 208.60 |
| High | 210.39 |
| Low | 210.39 |
| Volume [EUR] | - |
| Volume [Units] | 0 |
| Price fixings | 1 |
| ISIN | US09062X1037 |
| Security | BIIB |
| Exchange | Vienna Global Market |
| Type | Stock |
| Exchange | Last | Volume | |
|---|---|---|---|
| TradeGate | 211.050 |  |
48 |
| Vienna Globa.. | 210.39 |  |
0 |
| München | 209.40 | |
0 |
| Hamburg | 209.40 | |
0 |
| Düsseldorf | 209.35 | |
0 |
| Berlin | 210.30 | |
0 |
| Frankfurt | 209.3500 | |
0 |
| Hannover | 209.40 | |
0 |
| Lang & Schwa.. | 209.350 | |
|
| gettex | 209.800 | |
|
| Stuttgart | 209.250 | |
|
| NASDAQ | 232.0600 | |
732,929 |
| Cboe US | 232.08 | |
38,377 |
| IEX | 232.03 | |
28,205 |
| London Inter.. | 231.95 | 445 | |
| Mexico | 4,440.20 |  |
5 |
| Xetra | 208.80 | 0 | |
| SIX Swiss Ex.. | 232.00 |
News
- Global Personalized Medicine (PM) Market Anticipated to Near $3.2 Trillion by 2025 - PM Therapeutics is Projected to Register the Fastest CAGR
08/21/2019 / 14:09 - GlobeNewswire - Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
08/20/2019 / 13:30 - GlobeNewswire - Neurologic Disorders Therapeutics: Global Market Analysis Through 2019-2023 with Biogen, Roche, Johnson & Johnson Services, Novartis, and Pfizer Leading
08/19/2019 / 10:05 - GlobeNewswire - Global Hemophilia Market Outlook 2019-2024: Focus on Recombinant, Immune Tolerance Induction (ITI), and Gene Therapies
08/01/2019 / 15:41 - GlobeNewswire - Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
07/30/2019 / 13:30 - GlobeNewswire
Real-time